We are live on
!
Find out more
LVTX
LAVA Therapeutics
LVTX
LVTX
Delisted
LVTX was delisted on the 20th of November, 2025.
13 hedge funds and large institutions have $34.1M invested in LAVA Therapeutics in 2022 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 6 closing their positions.
New
Increased
Maintained
Reduced
Closed
49% more capital invested
Capital invested by funds: $22.8M → $34.1M (+$11.2M)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
1.5% less ownership
Funds ownership: 30.41% → 28.91% (-1.5%)
24% less funds holding
Funds holding: 17 → 13 (-4)
67% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 6
Holders
13
Holders Change
-4
Holders Change %
-23.53%
% of All Funds
0.22%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
2
Reduced
2
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$1.68M |
| 2 |
UOC
UBS O'Connor
Chicago,
Illinois
|
+$206K |
| 3 |
CC
Cannell Capital
Alta,
Wyoming
|
+$38.3K |
| 4 |
Axa
Paris,
France
|
+$3.3K |
